利拉鲁肽和司美格鲁肽对降低2型糖尿病患者同型半胱氨酸水平的潜在作用
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

南京市卫生科技发展专项基金资助项目(YKK19175);


The potential impact of liraglutide and semaglutide on reducing homocys-teine levels in patients with type 2 diabetes mellitus
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
    摘要:

    目的:探讨利拉鲁肽和司美格鲁肽对降低在2型糖尿病(T2DM)患者中同型半胱氨酸(Hcy)水平的潜在作用。方法:选取108例T2DM患者为研究对象,根据治疗方式不同分为利拉鲁肽组(n=56,接受利拉鲁肽治疗)和司美格鲁肽组(n=52,接受司美格鲁肽治疗),均治疗连续12周。比较两组患者糖脂代谢指标水平、血清Hcy水平、炎症因子等水平、不良反应发生情况及治疗成本-效益。结果:治疗4、12周后,两组患者空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、Hcy、ApoA1/ApoB、C反应蛋白(CRP)水平均较治疗前降低,25羟维生素D[25(OH)D]水平较治疗前升高(P<0.05);治疗12周后,利拉鲁肽组患者FPG、2 hPG、HbA1c、Hcy、水平均较治疗4周后时降低,25(OH)D水平较治疗4周后时升高(P<0.05);治疗4周后,两组患者FPG、2 hPG、HbA1c、Hcy、ApoA1/ApoB、CRP、25(OH)D水平比较,差异无统计学意义(P>0.05);治疗12周后,司美格鲁肽组患者FPG、2 hPG、HbA1c、Hcy水平高于拉鲁肽组,25(OH)D水平低于利拉鲁肽组(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05);利拉鲁肽组治疗成本-效益较司美格鲁肽组更低。结论:在T2DM治疗早期,利拉鲁肽和司美格鲁肽均能有效改善糖脂代谢,降低炎症因子和Hcy水平,但随着治疗时间延长,利拉鲁肽对糖脂代谢、炎症因子和Hcy的改善情况优于司美格鲁肽,且经济效益较司美格鲁肽更高。

    Abstract:

    Objective:To explore the potential impact of liraglutide and semaglutide on reducing homocysteine(Hey)levels in patients with type 2 diabetes mellitus(T2DM).Methods:A total of 108 patients with T2DM were selected and divided into liraglutide group(n=56,all received liraglutide)and semaglutide group(n=52,all received semaglutide)according to different treatment meth-ods,both treated continuously for 12 weeks.The levels of glucose and lipid metabolism indicators,serum Hey levels,inflammatory factor levels,incidence of adverse reactions,and cost-effectiveness of treatment were compared between the two groups.Results:After 4 and 12 weeks of treatment,the levels of fasting plasma glucose(FPG),2-hour postprandial plasma glucose(2 hPG),glycosylated hemoglobin(HbA1c),homocysteine(Hey),ApoA1/ApoB,and C-reactive protein(CRP)in both groups exhibited a decrease compared to pre-treatment levels.Additionally,the level of 25-hydroxyvitamin D[25(OH)D]showed a notable increase after treatment initiation(P<0.05).After 12 weeks of treatment,the FPG,2 hPG,HbA1c,and Hcy levels in liraglutide group were lower compared to those observed after only 4 weeks of treatment.Moreover,their level of 25(OH)D was higher than that seen after 4 weeks of treatment(P<0.05).There were no statistically significant differences between the two groups regarding FPG,2 hPG,HbA1c,Hcy,ApoA1/ApoB CRP or 25(OH)D levels following 4 weeks of treatment(P>0.05).However,after completing a full course of twelve-weeks'therapy with sema-glutide or liraglutide respectively,the semaglutide group displayed higher FPG,2 hPG,Hb AIC,and HCy values when compared to the liraglutide group.Furthermore,the levelof vitamin D(25-OHD3)was lower in patients treated with semagluti decomparedtothose treated with liraglutide(P<0.05).There was no statistically significant difference in terms o f adverse reactions incidence between these two groups(P>0.05).The cost-effectiveness analysis revealed that liraglutide was more economical than semaglutide.Conclusion:In the initial phase of T2DM,liraglutide and semaglutide demonstrate effective enhancement in glucose and lipid metabolism while reducing in-flammatory factors and Hcy levels.Their clinical effects are comparable.However,with prolonged treatment duration,liraglutide showed better improvement in glucose and lipid metabolism,inflammatory factors,and Hcy compared to semaglutide,and had higher economic benefits.

    参考文献
    相似文献
    引证文献
引用本文

张倩;张敏;项丹;吴倩;丁利;王坚;王扬天;.利拉鲁肽和司美格鲁肽对降低2型糖尿病患者同型半胱氨酸水平的潜在作用[J].川北医学院学报,2025,40(2):215-219.

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2025-07-24
  • 出版日期:
文章二维码